Current treatment status-Undergoing active treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment Posts on Medivizor

Bone damage in children with ALL.

Posted by on Oct 4, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the risk of osteonecrosis (ON – bone death/damage) as a treatment complication in children with acute lymphoblastic leukemia (ALL). The study found that older age and steroid drugs were risk factors for ON in the treatment of ALL. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the bone marrow...

Read More

The impact of monitoring time on disease outcomes and treatment cost in patients with chronic myeloid leukemia

Posted by on Sep 27, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the effect of early monitoring on disease progression and treatment cost in patients with chronic myeloid leukemia (CML). Researchers found that patients with CML who are monitored earlier may have better outcomes and lower treatment costs. Some background Chronic Myeloid Leukemia (CML) is a progressive cancer...

Read More

Lenalidomide consolidation therapy for patients receiving chemoimmunotherapy for chronic lymphocytic leukemia

Posted by on Sep 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of lenalidomide consolidation therapy after chemoimmunotherapy for patients with chronic lymphocytic leukemia. This study concluded that this regimen improves outcomes for these patients. Some background Fludarabine (Fludara) is a chemotherapy used for the treatment of chronic lymphocytic...

Read More

Evaluating the effectiveness of stem cell transplant in patients with follicular lymphoma with early treatment failure

Posted by on Sep 9, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness of autologous stem cell transplantation (autoSCT) for patients with follicular lymphoma who experienced early treatment failure (ETF; relapse or disease progression within 2 years after first-line therapy). This study concluded that autoSCT may be an effective option for these patients. Some...

Read More

Evaluating rituximab maintenance therapy in patients with newly diagnosed follicular lymphoma

Posted by on Sep 6, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of rituximab (Rituxan) maintenance therapy in patients with newly diagnosed follicular lymphoma (FL). This study concluded that this therapy improves survival outcomes in these patients. Some background For patients with early (stage 1 – 2) FL, aggressive radiotherapy or...

Read More

Surgery improves survival of colorectal cancer patients with lung metastasis

Posted by on Aug 17, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the outcomes of surgery to lung metastasis (LM; cancer spreads to the lungs) in patients with colorectal cancer. Researchers suggested that lung surgery increases the survival of these patients.   Some background Colorectal cancer is one of the major diseases seen in the US. LM appear in 5-15% of patients and...

Read More

Nilotinib versus imatinib in the treatment of CML

Posted by on Aug 13, 2018 in Leukemia | 0 comments

In a nutshell This study compared the effectiveness of nilotinib (Tasigna) with high-dose imatinib (Glivec) in patients with unresponsive chronic myeloid leukemia. Researchers concluded that nilotinib may be more effective as a long-term treatment for CML when compared to imatinib. Some background Chronic myeloid leukemia is a cancer of the bone...

Read More

Evaluating cardiovascular safety of carfilzomib in patients with relapsed or refractory multiple myeloma

Posted by on Aug 10, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the cardiovascular (heart and blood vessels) safety of carfilzomib (Kyprolis) in patients with relapsed or refractory (does not respond to treatment) multiple myeloma. This study concluded that the benefits of carfilzomib outweighed its risks. Some background Multiple myeloma is a type of cancer of the bone...

Read More

Maintenance rituximab plus bortezomib for mantle cell lymphoma

Posted by on Aug 1, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of rituximab (Rituxan) plus bortezomib (Velcade) for patients with mantle cell lymphoma after stem cell transplant. This study concluded that this combination is a safe and effective regimen in these patients. Some background The standard treatment for younger patients with mantle cell...

Read More